breast cancer

Is the PRESENT study the key for a new vaccine for breast cancer?

flower A small biopharma company (Galena) released crucial information on it's breast cancer vaccine (NeuVax).

Company: 
Galena

Breast cancer and traztuzumab plus neratinib target drug therapy hope

 

beautiful woman  Breast Cancer cures and targeted drug therapy hope may be realized with a novel combination of two powerful drugs that is being undertaken at the Cleveland Clinic. I think this deserves a closer look.

FDA moves to remove breast cancer indication from Avastin (bavacizumab)

telephones  The FDA announced today that it has started the process to remove approval (the indication) for use of Avastin (bavacizumab) in breast cancer.  They came to this conclusion after reviewing four more recent studies which lead them to decide that the drug has not been found to be safe and effective in those p

Members Only: 

telephones  The FDA announced today that it has started the process to remove approval (the indication) for use of Avastin (bavacizumab) in breast cancer.  They came to this conclusion after reviewing four more recent studies which lead them to decide that the drug has not been found to be safe and effective in those patients.  It’s important to remember that the existing approval for use in brain, colon, kidney and lung cancer is still in place.

Now that the agency has started the process, the manufacturer (Genentech) has 15 days to ask for a hearing in response to the FDA ‘Notice of Opportunity”. If it requests such a hearing, it will be public and if not, the process to remove the indication for breast cancer will be started.

Physicians already using Avastin to treat breast cancer were encouraged by the FDA to use their medical judgment to decide to continue the treatment or opt for other medicines.

lab equipment The director (Janet woodcock, MD) of the Center for Drug Evaluation and Research (CDER) noted that the FDA decision was based on careful review of the four most recent studies. It found that these newer studies failed to confirm the benefit seen in the original trial and that none of the research showed Avastin breast cancer patients to live longer and appeared to expose them to a significant increase in serious side effects (such as stroke, organ failure or damage or RPLS).

Dr. Woodcock’s comments followed the advisory committee vote this past July of 12 to 1 for removal of the breast cancer indication. Further comments were made that there was a small increase in the amount of time patients lived without cancer progression (progression-free survival), but it was thought that this merely reflected a temporary effect on slowing tumor growth. The FDA was balanced in its review and asked Genentech to undertake new research or make proposals for additional studies which might identify some patients with breast cancer which has spread (metastatic breast cancer) who might benefit from Avastin therapy. See the full press release at www.fda.gov.

Yearly mammograms starting when you are 40 may cut mastectomy risk in half

beautiful black haired woman New research released from the RS&A (Radiological Society of North America) meeting found that women who started getting yearly  mammograms when they were 40, were able to cut their risk of breast removal (mastectomy) by half versus women who did not avail themselves of this benefit o

Members Only: 

beautiful black haired woman New research released from the RS&A (Radiological Society of North America) meeting found that women who started getting yearly  mammograms when they were 40, were able to cut their risk of breast removal (mastectomy) by half versus women who did not avail themselves of this benefit or who were in the United Kingdom and fell under their standards where yearly mammograms only start at age 50.  

members circle

As usual, this points out the importance of catching any cancer early and while chemotherapy has improved, early detection is a great help. The author of the paper (Dr. Nicholas Perry) presented this abstract (SSQ01-08.

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.